0001104659-24-062528.txt : 20240516 0001104659-24-062528.hdr.sgml : 20240516 20240516161124 ACCESSION NUMBER: 0001104659-24-062528 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240516 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240516 DATE AS OF CHANGE: 20240516 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ArriVent BioPharma, Inc. CENTRAL INDEX KEY: 0001868279 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41929 FILM NUMBER: 24955661 BUSINESS ADDRESS: STREET 1: 18 CAMPUS BLVD. STREET 2: SUITE 100 CITY: NEWTOWN SQUARE STATE: PA ZIP: 19073-3269 BUSINESS PHONE: 240-780-6356 MAIL ADDRESS: STREET 1: 18 CAMPUS BLVD. STREET 2: SUITE 100 CITY: NEWTOWN SQUARE STATE: PA ZIP: 19073-3269 FORMER COMPANY: FORMER CONFORMED NAME: ArriVent Biopharma, Inc. DATE OF NAME CHANGE: 20210617 8-K 1 tm2414720d1_8k.htm FORM 8-K
false 0001868279 0001868279 2024-05-16 2024-05-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT 

Pursuant to Section 13 or 15(d) 

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 16, 2024

 

ARRIVENT BIOPHARMA, INC. 

(Exact name of registrant as specified in its charter)

 

Delaware   001-41929   86-3336099
(State or other jurisdiction
of incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

 

18 Campus Boulevard, Suite 100

Newtown Square, PA

   19073
(Address of principal executive offices)   (zip code)

 

Registrant’s telephone number, including area code: (628) 277-4836

 

N/A 

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading
Symbol(s)		   Name of each exchange
on which registered
Common Stock, $0.0001 par value per share   AVBP   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging Growth Company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

 

Item 5.02              Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On May 16, 2024, the Board of Directors (the “Board”) of ArriVent BioPharma, Inc. (the “Company”) appointed John Hohneker, M.D., to the Board, effective as of May 16, 2024 (the “Effective Date”). Dr. Hohneker will serve as a Class II Director until the Company’s 2026 annual meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation, retirement or removal.

 

Dr. Hohneker, age 64, most recently served as President and Chief Executive Officer of Anokion SA, a Swiss biotechnology company, from January 2018 to February 2021. Prior to Anokion SA, he led Research and Development at Forma Therapeutics (“Forma”), a biotechnology company, from August 2015 to January 2018. Prior to Forma, Dr. Hohneker held various leadership roles during his 14 years at Novartis AG, from 2001 to 2015, where he most recently served as Senior Vice President and Global Head of Development, Immunology and Dermatology. Dr. Hohneker also currently serves on the board of directors for the following companies: Carisma Therapeutics, Inc. (Nasdaq: CARM), a publicly traded biotechnology company focused on discovering and developing innovative immunotherapies; Curis, Inc. (Nasdaq: CRIS), a publicly traded biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer; Sonata Therapeutics, a private research stage biotechnology company, and Trishula Therapeutics, a private clinical-stage biotechnology company targeting cancer immunotherapy. Dr. Hohneker received a bachelor’s degree in chemistry from Gettysburg College and a medical degree from the University of Medicine and Dentistry of New Jersey at Rutgers Medical School.

 

The Board has affirmatively determined that Dr. Hohneker is an independent director pursuant to the Nasdaq Stock Market’s governance listing standards and the rules and regulations issued pursuant to the Securities Exchange Act of 1934, as amended. There are no arrangements or understandings between Dr. Hohneker and any other person pursuant to which Dr. Hohneker was appointed as a director. There are no transactions to which the Company is a party and in which Dr. Hohneker has a material interest that are required to be disclosed under Item 404(a) of Regulation S-K. Dr. Hohneker has not previously held any positions with the Company and has no family relations with any directors or executive officers of the Company. Currently, the Board has not made a determination regarding any committee assignments for Dr. Hohneker.

 

Dr. Hohneker will be entitled to the standard compensation paid by the Company to its non-employee directors under the Company’s Non-Employee Director Compensation Policy (the “Non-Employee Director Compensation Policy”). Pursuant to the Non-Employee Director Compensation Policy, on the Effective Date, Dr. Hohneker was granted a non-qualified stock option to purchase shares of the Company’s common stock, effective as of the Effective Date (the “Grant Date”), with a Grant Date fair value of $352,500 (the “Initial Option Award”). The Initial Option Award will vest annually over three years following the Grant Date, subject to Dr. Hohneker continuing to provide services to the Company through each such vesting. In addition, Dr. Hohneker is entitled to receive an annual cash retainer of $45,000 for his service as a non-employee director of the Company pursuant to the Non-Employee Director Compensation Policy, prorated for the portion of the year that Dr. Hohneker serves as a director. Furthermore, pursuant to the Non-Employee Director Compensation Policy, Dr. Hohneker is entitled to receive an annual grant of non-qualified stock options to purchase shares of the Company’s common stock on the first business day after the Company’s annual meeting of stockholders (the “Annual Option Grant Date”), with a grant date fair value of $235,000 (the “Annual Option Award”). The Annual Option Award will vest on the first anniversary of the Annual Option Grant Date, subject to Dr. Hohneker continuing to provide services to the Company through such vesting.

 

Dr. Hohneker will also enter into an indemnification agreement in the form the Company has entered into with its other non-employee directors, which form is filed as Exhibit 10.1 to the Company’s Registration Statement on Form S-1, as amended (File No. 333-276397), filed with the Securities and Exchange Commission on January 5, 2024.

 

A copy of the press release announcing Dr. Hohneker’s appointment to the Board is attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

 

 

Item 9.01              Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
99.1   Press Release dated May 16, 2024.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  ARRIVENT BIOPHARMA, INC.
     
  By: /s/ Winston Kung, MBA
    Winston Kung, MBA
    Chief Financial Officer and Treasurer

 

Date: May 16, 2024

 

 

 EX-99.1 2 tm2414720d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

ArriVent Appoints John Hohneker, M.D., to its Board of Directors

 

NEWTON SQUARE, PA – May 16, 2024 – ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of John Hohneker, M.D. to its Board of Directors. Dr. Hohneker brings over 30 years of experience in biopharmaceutical leadership and drug development, and currently serves on the Boards of public companies Carisma Therapeutics, Inc. and Curis, Inc., and private companies Sonata Therapeutics and Trishula Therapeutics.

 

“We are excited to welcome Dr. Hohneker to our Board of Directors and look forward to his partnership as we work to advance our pipeline, including our lead candidate firmonertinib, and address the unmet needs of cancer patients,” said Bing Yao, Chairman and Chief Executive Officer of ArriVent. “Dr. Hohneker brings significant medical affairs, drug development and strong market launch experience that will support the continued development of our differentiated programs.”

 

“I am thrilled to join the ArriVent Board of Directors, not only due to the company’s strong pipeline momentum, but because of the team’s passion for providing patients with potentially transformative medicines,” said Dr. Hohneker. “I have dedicated my career to addressing the unmet needs of patients, and I look forward to continuing that work with ArriVent.”

 

Most recently, Dr. Hohneker served as President and Chief Executive Officer of Anokion SA. Prior to this role, Dr. Hohneker was President of Research and Development at Forma Therapeutics, Inc., where he guided the company’s transition from a discovery-stage biotech to a clinical-stage company. Previously, Dr. Hohneker held various leadership roles during his 14 years at Novartis AG, including Senior Vice President and Global Head of Development, Immunology and Dermatology. During his tenure at Novartis, he played a key role in the development, approval and commercialization of several products. Dr. Hohneker earned his B.A. in chemistry from Gettysburg College and his M.D. from the University of Medicine and Dentistry of New Jersey at Rutgers Medical School.

 

About ArriVent

 

ArriVent is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. ArriVent seeks to utilize its team’s deep drug development experience to maximize the potential of its lead development candidate, firmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization.

 

About Firmonertinib

 

Firmonertinib (formerly furmonertinib) is an oral, highly brain-penetrant, and broadly active mutation-selective epidermal growth factor receptor (EGFR) inhibitor active against both classical and uncommon EGFR mutations, including PACC and exon 20 insertion mutations. In March 2021, firmonertinib was approved in China for first-line advanced non-small-cell lung cancer (NSCLC) with EGFR exon 19 deletion or L858R mutations and for patients with previously treated locally advanced or metastatic NSCLC with EGFR T790M mutation, otherwise known as EGFR classical mutations.

 

1

 

 

 

In October 2023, firmonertinib was granted U.S. Food and Drug Administration Breakthrough Therapy Designation for the treatment of patients with previously untreated locally advanced or metastatic non-squamous NSCLC with EGFR exon 20 insertion mutations.

 

Firmonertinib is currently being studied in a global Phase 3 trial for first-line NSCLC patients with EGFR exon 20 insertion mutations (FURVENT; NCT05607550) and in a global Phase 1b study evaluating firmonertinib in patients EGFR PACC mutations (FURTHER; NCT05364043). In addition, firmonertinib is also being studied in a clinical combination study targeting advanced or metastatic NSCLC patients with EGFR classical mutations, in partnership with InnoCare Pharma.

 

About EGFR mutant NSCLC

 

Globally, lung cancer is the leading cause of cancer-related deaths among men and women. NSCLC is the predominant subtype of lung cancer, accounting for approximately 85% of all cases. Mutational activation of the EGFR is a frequent and early event in the development of NSCLC. EGFR mutations are divided into classical and uncommon. EGFR exon 20 insertion mutations are a group of uncommon EGFR mutations and constitute approximately 9% of all EGFR mutations. PACC mutations are another group of uncommon EGFR mutations and represent approximately 12% of all EGFR mutations. Patients with NSCLC whose tumors harbor uncommon EGFR mutations have significantly lower life expectancy with available therapies and represent an area of unmet medical need.

 

Forward-Looking Statements

 

This press release includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding ArriVent’s ability to develop drugs that help to address the unmet needs of cancer patients, the timing, progress and results of pre-clinical studies and clinical trials for firmonertinib, including our product development plans and strategies, ArriVent’s clinical programs, future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Forward-looking statements are based on ArriVent’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties that are described more fully in the section titled “Risk Factors” in ArriVent’s annual report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission on March 28, 2024, and its other filings with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and ArriVent undertakes no duty to update such information except as required under applicable law.

 

Contact for Investors & Media:

Argot Partners

212.600.1902

ArriVent@argotpartners.com

 

2

 

 EX-101.SCH 3 avbp-20240516.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 avbp-20240516_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 avbp-20240516_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2414720d1_ex99-1img001.jpg GRAPHIC begin 644 tm2414720d1_ex99-1img001.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cover
May 16, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 16, 2024
Entity File Number 001-41929
Entity Registrant Name ARRIVENT BIOPHARMA, INC.
Entity Central Index Key 0001868279
Entity Tax Identification Number 86-3336099
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 18 Campus Boulevard
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Newtown Square
Entity Address, State or Province PA
Entity Address, Postal Zip Code 19073
City Area Code 628
Local Phone Number 277-4836
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol AVBP
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

-8?20$3;8T.P6BP^0"X99K>]9!:G%C:^?VZH:TE[VE-S9NMQ=%A?BTX'HE'QY%V)N M:I%FGJ:QJ,';>$<-!)U4Q-Z*0CZFL6&P9:P!Q+MTFF6SU%L,9KD8M;:X1+_)UW,#ECQ ,ZE._<]'<')O$8T.,5RMQD)HDU75Z(\4I!K-L5 M3,[E9C(,]L""Q1]ZUYG\M(?8,V(/'U:-Y&:6J6"%'*7?Z/6M>CR#+@^H%7I" M)\!K*_#,U#88CIV,IDAO8O0]C.=0XIS_4R-5%1:PIJ+U$&3HD<%U!D.LL8DF M"=9#;E9T!N[RZ .;O\P>=0>6N=6RKV'5[+E&''\GN4/4$L#!!0 ( &N!L%@D'INBK0 /@! M : >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U M4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL& MRF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*'3^ 5!+ P04 " !K@;!899!YDAD! M #/ P $P %M#;VYT96YT7U1Y<&5S72YX;6RMDTU.PS 0A:\295LE+BQ8 MH*8;8 M=< %C3QJK_I-G6M+;,T[:2J 2%85-K'C>O,^>EZS>CQ&PZ)WUV)0= M47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0P1-XJBA[E.O5,[1R;ZEX MZ7D;3?!-FI6.5Z*U .EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1 M=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN# MOI'-X_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 M Q0 ( &N!L%@'04UB@0 +$ 0 " 0 !D;V-0 M&UL4$L! A0#% @ :X&P6$#DRY;N *P( !$ M ( !KP &1O8U!R;W!S+V-O&UL4$L! A0#% @ :X&P M6)E&PO=V]R:W-H965T&UL4$L! A0#% @ :X&P M6)^@&_"Q @ X@P T ( !W@P 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! A0#% @ :X&P6"0> MFZ*M ^ $ !H ( ! Q( 'AL+U]R96QS+W=O9(9 0 SP, !, M ( !Z!( %M#;VYT96YT7U1Y<&5S72YX;6Q02P4& D "0 ^ @ &,A0 end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://arrivent.com/role/Cover Cover Cover 1 false false All Reports Book All Reports avbp-20240516.xsd avbp-20240516_lab.xml avbp-20240516_pre.xml tm2414720d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2414720d1_8k.htm": { "nsprefix": "avbp", "nsuri": "http://arrivent.com/20240516", "dts": { "schema": { "local": [ "avbp-20240516.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "avbp-20240516_lab.xml" ] }, "presentationLink": { "local": [ "avbp-20240516_pre.xml" ] }, "inline": { "local": [ "tm2414720d1_8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://arrivent.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-05-16", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2414720d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-05-16", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2414720d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://arrivent.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001104659-24-062528-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-062528-xbrl.zip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end XML 18 tm2414720d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001868279 2024-05-16 2024-05-16 iso4217:USD shares iso4217:USD shares false 0001868279 8-K 2024-05-16 ARRIVENT BIOPHARMA, INC. DE 001-41929 86-3336099 18 Campus Boulevard Suite 100 Newtown Square PA 19073 628 277-4836 false false false false Common Stock, $0.0001 par value per share AVBP NASDAQ true false